WO2014123077A1 - Matériau de revêtement médical et dispositif médical - Google Patents

Matériau de revêtement médical et dispositif médical Download PDF

Info

Publication number
WO2014123077A1
WO2014123077A1 PCT/JP2014/052322 JP2014052322W WO2014123077A1 WO 2014123077 A1 WO2014123077 A1 WO 2014123077A1 JP 2014052322 W JP2014052322 W JP 2014052322W WO 2014123077 A1 WO2014123077 A1 WO 2014123077A1
Authority
WO
WIPO (PCT)
Prior art keywords
copolymer
present
segment
medical
coating
Prior art date
Application number
PCT/JP2014/052322
Other languages
English (en)
Japanese (ja)
Inventor
崇王 安齊
友恵 袴谷
Original Assignee
テルモ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テルモ株式会社 filed Critical テルモ株式会社
Publication of WO2014123077A1 publication Critical patent/WO2014123077A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/08—Materials for coatings
    • A61L29/085—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/06—Use of macromolecular materials
    • A61L33/064—Use of macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds

Definitions

  • the present invention relates to a medical coating material and a medical device coated with the material. More specifically, the present invention relates to a medical coating material excellent in hydrophilicity and a medical device coated with the material.
  • medical devices such as plasma separation membranes, catheters, artificial lung membranes, artificial blood vessels, and artificial organs have been used for the treatment of various diseases with the improvement of medical technology. Since these medical devices come into contact with blood, body fluids or biological tissues for a long time, affinity with blood, body fluids or biological tissues, and blood compatibility (antithrombogenicity) to prevent blood coagulation are required. ing.
  • Patent Document 1 is a copolymer having, as monomer components, an alkoxyalkyl (meth) acrylate monomer represented by the following formula (1) and a monomer having a basic functional group that can be copolymerized with the monomer.
  • the molar ratio of the amount of the monomer represented by the following formula (1) and the amount of the monomer having a basic functional group is 85/15 to 99.9 / 0.1, and the number average molecular weight is 5,
  • An antithrombotic surface treatment agent comprising a copolymer having a molecular weight of 000 to 500,000 and a medical device surface-treated with the antithrombotic surface treatment agent are disclosed. Further, an antithrombotic agent in which an alkoxyalkyl (meth) acrylate and a copolymer having a basic functional group copolymerizable therewith in a specific molar ratio, and an antithrombotic material comprising the copolymer are excellent in antithrombosis It is described that it can exhibit the property and hydrophilicity.
  • R 1 represents an alkylene group having 1 to 4 carbon atoms
  • R 2 represents an alkyl group having 1 to 4 carbon atoms
  • R 3 represents a hydrogen atom or a methyl group.
  • JP 2002-105136 A (corresponding to US Patent Application Publication No. 2002/0064558)
  • the present invention has been made in view of the above circumstances, and an object thereof is to provide a medical coating material excellent in hydrophilicity and a medical device coated with the material.
  • a medical coating material containing a copolymer having a segment A having a structural unit derived from vinylimidazole and a segment B having a structural unit derived from vinyl monomer.
  • FIG. 1 shows a photograph of the surface of a polypropylene film having a coating layer formed of the copolymer (3) obtained in Example 3 observed with a scanning electron microscope (SEM).
  • FIG. 2 shows a photograph of the surface of a polypropylene film not coated with a polymer (Comparative Example 1) observed with a scanning electron microscope (SEM).
  • the medical coating material of the present invention comprises a segment A having a structural unit derived from vinylimidazole (also referred to herein as “segment A”) and a segment B having a structural unit derived from vinyl monomer (herein referred to as “segment A”). , Also referred to as “segment B”) (also referred to herein as “copolymer according to the invention”).
  • the medical coating material of the present invention is characterized by using a copolymer having segment A and segment B. Since the copolymer according to the present invention (hence, the coating layer containing the medical coating material of the present invention and the copolymer according to the present invention) has high hydrophilicity, it is excellent in antithrombogenicity (particularly, adhesion of platelets and adhesion prevention). In addition, it has excellent antibacterial properties.
  • the mechanism by which the copolymer according to the present invention exhibits excellent antithrombogenicity (particularly platelet adhesion / adhesion prevention) and antibacterial properties is unknown, but is presumed as follows. The present invention is not limited by the following estimation.
  • the segment A constituting the copolymer according to the present invention has a structural unit derived from vinylimidazole.
  • vinylimidazole is a water-soluble polymer.
  • the pKa of the imidazole group is 5.9, it is nonionic and hydrophilic under a physiological environment (pH about 7.4).
  • a polymer having a constitutional unit derived from vinylimidazole forms a nonionic and hydrophilic coat layer in a physiological environment. Therefore, a coat layer containing a copolymer having segment A has blood compatibility and antithrombotic properties.
  • the copolymer according to the present invention can be a thrombus adhesion suppression / prevention material.
  • Vinyl imidazole itself has antibacterial properties.
  • the copolymer according to the present invention having segment A also exhibits excellent antibacterial properties, that is, the copolymer according to the present invention can also be an antibacterial material.
  • the copolymer of the present invention has a segment B, and can be firmly bonded to the substrate through the segment B. For this reason, since the copolymer according to the present invention is firmly bonded (fixed) to the base material via the segment B, peeling of the coat layer from the base material can be suppressed / prevented. Therefore, the copolymer according to the present invention having segment B can maintain the thrombus adhesion suppression / prevention (antithrombogenicity) and antibacterial properties by segment A for a long period of time.
  • the copolymer itself according to the present invention having segment A and segment B has antithrombotic properties (particularly platelet adhesion / adhesion prevention properties) and antibacterial properties, and also has various high functions that constitute medical devices.
  • a stable coating layer can be firmly bonded (immobilized) to the surface of the molecular material or metal material by a simple coating process.
  • a medical coating material having excellent hydrophilicity and a medical device coated with the material can be provided.
  • the medical device of the present invention has a platelet adhesion number (thrombus adhesion suppression / prevention) in the “platelet adhesion test” in the following examples of 0 to 130, more preferably 0 to 50, The number is preferably 0-20.
  • the lower limit of the platelet adhesion number (thrombus adhesion suppression / prevention property) in the “platelet adhesion test” is zero as it is preferably lower.
  • X to Y indicating a range means “X or more and Y or less”, “weight” and “mass”, “weight%” and “mass%”, “part by weight” and “weight part”. “Part by mass” is treated as a synonym. Unless otherwise specified, measurements such as operation and physical properties are performed under conditions of room temperature (20 to 25 ° C.) / Relative humidity 40 to 50%.
  • the medical coating material includes the copolymer according to the present invention.
  • the medical coating material may contain other additives, drugs (bioactive substances), and the like.
  • the medical coating material is preferably composed only of the copolymer according to the invention.
  • the copolymer according to the present invention has a segment A having a structural unit derived from vinylimidazole and a segment B having a structural unit derived from vinyl monomer.
  • Segment A includes:
  • a structural unit derived from vinylimidazole As described above, a segment having a structural unit derived from vinylimidazole imparts thrombus adhesion suppression / prevention and antibacterial properties to a medical device (coat layer).
  • the segment A may have a structural unit (other structural unit) other than the structural unit derived from vinylimidazole.
  • other structural units are not particularly limited as long as the effects (thrombus adhesion suppression / prevention, antibacterial properties, etc.) according to the present invention are not impaired.
  • R 4 represents a hydrogen atom or a methyl group
  • R 5 represents a linear or branched alkylene having 1 to 4 carbon atoms, such as a methylene group, an ethylene group, a trimethylene group, a propylene group, or a tetramethylene group
  • R 6 represents a straight chain or branched chain having 1 to 4 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, etc.
  • the said other structural unit may exist individually by 1 type, and may exist in 2 or more types of mixed forms.
  • the composition (ratio) of the other structural units is particularly limited as long as the effects (thrombus adhesion suppression / prevention, antibacterial properties, etc.) according to the present invention are not impaired.
  • the proportion of other structural units present in the segment A is preferably about 5 to 30 mol%, and more preferably about 7 to 15 mol%.
  • Segment B has a structural unit derived from a vinyl monomer.
  • a segment having a structural unit derived from a vinyl monomer imparts a coating property (hence, thrombus adhesion suppression / prevention maintenance property, antibacterial maintenance property, etc.) to a medical device (coat layer).
  • the structural unit derived from a vinyl monomer may exist individually by 1 type, and may exist with 2 or more types of mixed forms.
  • the structural unit derived from the vinyl monomer is not particularly limited as long as it has a vinyl group (CH 2 ⁇ C (R) —; R is a hydrogen atom or a methyl group), but is hydrophilic with a crosslinkable side chain.
  • a vinyl monomer or a hydrophobic vinyl monomer is preferred.
  • the constituent unit derived from the vinyl monomer has a binding property (reactivity) with the base material. It preferably has a functional group.
  • the functional group having a binding property (reactivity) with the base material is not particularly limited, and varies depending on the type of material forming the base material, but a carbonyl group, an epoxy group, an isocyanate group, an aldehyde group, and an acid. Preferred examples include a chloride group. Of these, a carbonyl group is more preferred.
  • Segment B having a structural unit derived from a vinyl monomer having such a functional group can be strongly bonded to the base material, and has superior coating properties (hence, thrombus adhesion suppression / prevention maintenance property, antibacterial properties). Maintainability).
  • hydrophilic vinyl monomer having a crosslinkable side chain the following formula (1):
  • R ⁇ 1 > is a hydrogen atom or a methyl group
  • Diacetone (meth) acrylamide represented by can be preferably used.
  • R ⁇ 1 > is a hydrogen atom or a methyl group.
  • Diacetone (meth) acrylamide which is a hydrophilic vinyl monomer having a crosslinkable side chain, exhibits room temperature crosslinkability. That is, the carbonyl group in the hydrophilic vinyl monomer having a crosslinkable side chain can be crosslinked under mild conditions in the presence of a crosslinking agent, or can form a covalent bond with the substrate.
  • the medical coating material containing a copolymer having a structural unit derived from a hydrophilic vinyl monomer having a crosslinkable side chain does not require heating or the like, under mild conditions that do not impair the physical properties of the substrate itself, It can be simply crosslinked or bonded (immobilized) to the surface of the substrate.
  • R 1 is preferably a hydrogen atom. That is, the structural unit derived from the vinyl monomer is preferably derived from diacetone acrylamide (DAAM).
  • alkyl (meth) acrylate represented by can be preferably used. Since the alkyl (meth) acrylate of the above formula (2) is hydrophobic, it can be firmly bonded (immobilized) to the surface of the substrate. For example, even if it is placed in a body fluid such as blood, It is preferable from the viewpoint of safety.
  • R ⁇ 2 > is a hydrogen atom or a methyl group.
  • R 2 is preferably a methyl group.
  • R 3 is an alkyl group having 4 to 10 carbon atoms.
  • the alkyl group is not particularly limited, but butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group, isopentyl group, neopentyl group, hexyl group, heptyl group, octyl group, 2- Examples thereof include linear or branched alkyl groups such as ethylhexyl group, nonyl group, and decyl group.
  • a butyl group, a pentyl group, and a hexyl group are preferable, and a butyl group is more preferable, from the viewpoints of coatability, thrombus adhesion suppression / prevention maintenance property, and antibacterial maintenance property.
  • the segment B may have a structural unit (other structural unit) other than the structural unit derived from the vinyl monomer.
  • the other structural units are not particularly limited as long as the effects (coatability, thrombus adhesion suppression / prevention maintenance property, antibacterial maintenance property, etc.) according to the present invention are not impaired, and other constitutional units described in segment A
  • the structural unit similar to a unit can be illustrated.
  • the other structural units may be present alone or in a mixed form of two or more.
  • the effects (coating properties, thrombus adhesion inhibition / prevention maintenance properties, antibacterial maintenance properties, etc.) of the present invention are impaired in the composition (ratio) of the other structural units.
  • the proportion of other structural units present in the segment B is preferably about 5 to 30 mol%, and more preferably about 7 to 15 mol%.
  • the composition of the copolymer (the ratio of segments A and B) is not particularly limited. Considering the effects (coatability, thrombus adhesion suppression / prevention property, thrombus adhesion suppression / prevention maintenance property, antibacterial property, antibacterial maintenance property, etc.) according to the present invention, the ratio of segment A to the total structural units constituting the copolymer is 15 It is preferable to exceed mol%.
  • segment A when the proportion of segment A is 15 mol% or less with respect to all the structural units constituting the copolymer, thrombus adhesion suppression / prevention and antibacterial properties due to segment A cannot be sufficiently exhibited, and thrombus adhesion suppression / prevention There is a possibility that medical coating materials with excellent antibacterial properties cannot be provided.
  • the ratio of segment A to all constituent units constituting the copolymer Is more preferably from 16 to 67 mol%, even more preferably from 17 to 60 mol%, particularly preferably from 20 to 50 mol%.
  • the types and compositions (ratio) of other structural units present in the segment A or the segment B may be the same or different. Similarly, other structural units may be present only in one of segment A or segment B, or may be present in both segments.
  • the segment A is preferably composed only of structural units derived from vinylimidazole.
  • the segment B is comprised only from the structural unit derived from a vinyl monomer. That is, the copolymer according to the present invention is particularly preferably composed of a structural unit derived from vinylimidazole and a structural unit derived from vinyl monomer.
  • the composition (ratio) of the structural unit derived from the vinyl imidazole and the structural unit derived from the vinyl monomer when the copolymer according to the present invention is composed of the structural unit derived from the vinyl imidazole and the structural unit derived from the vinyl monomer is not particularly limited. Specifically, the mixing ratio of the structural unit derived from vinyl imidazole and the structural unit derived from vinyl monomer (the molar ratio of the structural unit derived from vinyl imidazole to the structural unit derived from vinyl monomer) is 1: 0.4-6. It is preferably 1: 0.5 to 5, more preferably 1: 1 to 5, still more preferably 1: 1 to 4.
  • the copolymer having such a composition can achieve both good coatability, thrombus adhesion suppression / prevention property, thrombus adhesion suppression / prevention maintenance property, antibacterial property and antibacterial maintenance property by a simple coating process.
  • the terminal of the copolymer according to the present invention is not particularly limited and is appropriately defined depending on the kind of raw material used, but is usually a hydrogen atom.
  • the structure of the copolymer according to the present invention is not particularly limited, and may be any of a random copolymer, an alternating copolymer, a periodic copolymer, and a block copolymer. However, from the viewpoint of improving the film strength after coating on the substrate (strength of the crosslinked structure), a random copolymer in which crosslinking points are dispersed is preferable.
  • the weight average molecular weight of the copolymer according to the present invention is preferably 10,000 to 1,000,000, more preferably 30 from the viewpoints of coatability, thrombus adhesion suppression / prevention properties and thrombus adhesion suppression / prevention maintenance properties. 50,000 to 500,000, even more preferably 50,000 to 130,000, and particularly preferably 60,000 to 130,000.
  • the “weight average molecular weight” is a value measured by gel permeation chromatography (Gel Permeation Chromatography, GPC) using polystyrene as a standard substance.
  • the production method of the copolymer according to the present invention is not particularly limited, and the monomer (a) constituting the segment A, the monomer (b) constituting the segment B, and other structural units if necessary.
  • a method of copolymerizing the constituent monomer (c) with stirring and heating together with a polymerization initiator in a polymerization solvent can be used.
  • the polymerization initiator is not particularly limited, and known ones can be used.
  • 2,2′-azobisisobutyronitrile (AIBN) 2,2′-azobis-2-methylbutyronitrile, 2,2′-azobis (2-methylpropionic acid) dimethyl, 4,4 ′ -Azobis-4-cyanovaleric acid, azobisisovaleronitrile, 2,2'-azobis (2-amidinopropane) dihydrochloride, 2,2'-azobis [2- (5-methyl-2-imidazoline-2- Yl) propane] dihydrochloride, 2,2'-azobis (2-methylpropionamidine) disulfate, 2,2'-azobis (N, N'-dimethyleneisobutylamidine) dihydrochloride, 2,2'-azobis [N- (2-carboxyethyl) -2-methylpropionamidine] azo compounds such as hydrate (azo initiator); sodium persulfate, potassium persulfate Persulf
  • the said polymerization initiator can be used individually or in combination of 2 or more types.
  • the blending amount of the polymerization initiator is not particularly limited as long as the copolymerization of the monomers (a) and (b) can proceed efficiently, but the monomer (monomer (a) and single amount
  • the total amount of the body (b) 100 mol%) is preferably 0.0001 to 1 mol%.
  • the polymerization initiator may be a redox polymerization initiator.
  • the redox polymerization initiator is excellent in polymerization stability.
  • examples of such redox polymerization initiators include persulfates such as potassium persulfate (KPS), sodium persulfate, and ammonium persulfate; peroxides such as hydrogen peroxide, t-butyl peroxide, and methyl ethyl ketone peroxide.
  • a polymerization accelerator may be further added to the polymerization solvent as necessary.
  • the polymerization accelerator is not particularly limited, and known ones can be used.
  • a reducing agent such as sodium bisulfite, sodium sulfite, molle salt, sodium pyrobisulfite, sodium formaldehyde sulfoxylate, or ascorbic acid; ethylenediamine, sodium ethylenediaminetetraacetate, glycine, or N, N, N ′, N ′ -Amine compounds such as tetramethylethylenediamine; and the like can be used alone or in combination of two or more.
  • the blending amount of the polymerization accelerator is not particularly limited as long as it is an amount capable of promoting the copolymerization of the monomers (a) and (b), and the monomer (a) and the monomer (b) And it can select suitably according to the kind and addition amount of a polymerization initiator.
  • the polymerization solvent is not particularly limited, and can be appropriately selected depending on the types of the monomer (a), the monomer (b) and the polymerization initiator. Examples thereof include alcohol solvents such as methanol, ethanol, isopropanol and butanol, and non-proton donating organic solvents such as water, chloroform, tetrahydrofuran, acetone, dioxane and benzene.
  • the said polymerization solvent may be used individually by 1 type, and may use 2 or more types together.
  • the monomer concentration (solid content concentration) in the polymerization solvent is usually 10 to 90% by weight, preferably 15 to 80% by weight, and more preferably 20 to 80% by weight.
  • the concentration of the monomer in the polymerization solvent indicates the concentration of the total weight of the monomers (a) and (b).
  • the polymerization temperature during copolymerization is preferably 30 to 100 ° C. from the viewpoint of controlling the molecular weight.
  • the polymerization time is usually from 30 minutes to 24 hours.
  • a chain transfer agent a polymerization rate adjusting agent, a surfactant, and other additives may be appropriately used as needed during copolymerization.
  • the copolymer after copolymerization is preferably purified by a general purification method such as a reprecipitation method, a dialysis method, an ultrafiltration method, or an extraction method.
  • the copolymer according to the present invention and the medical coating material of the present invention are coated (coated, fixed) on the surface of the base material constituting the medical device and can be suitably used as a coating layer for covering the base material. . That is, according to the other one form of this invention, the medical device which has a base material and the coating layer containing the medical coating material of this invention formed on the said base material surface is provided.
  • the coating layer containing the medical coating material of the present invention can exhibit thrombus adhesion suppression / prevention properties, thrombus adhesion suppression / prevention maintenance properties, antibacterial properties, and antibacterial maintenance properties that are excellent in medical devices.
  • the medical device of the present invention is used in contact with blood, body fluid, or biological tissue.
  • an implantable prosthesis or treatment tool implanted
  • an extracorporeal circulation prosthetic organ e.g., an extracorporeal circulation prosthetic organ, a catheter, A guide wire etc.
  • implantable medical devices such as artificial blood vessels, artificial trachea, stents, artificial skin, and artificial pericardium that are inserted or replaced into blood vessels and lumens; artificial heart systems, artificial lung systems, and artificial kidney systems Artificial organ systems such as artificial liver systems and immunoregulatory systems; indwelling needles; IVH catheters, drug solution administration catheters, thermodilution catheters, angiographic catheters, vasodilator catheters and dilators or introducers Catheters inserted or indwelled, or guide wires and stylets for these catheters; gastric catheters, nutrition catheters, tube feeding (ED) tubes, urethral catheters, urinary catheters, endotracheal suction catheters
  • the copolymer according to the present invention having segment A is excellent in thrombus adhesion inhibition / prevention (antithrombogenicity) and antibacterial properties, and the copolymer according to the present invention having segment B is firmly fixed to the substrate via segment B. It is possible to For this reason, in the medical device of the present invention, the coat layer can exhibit excellent thrombus adhesion suppression / prevention properties, thrombus adhesion suppression / prevention maintenance properties, antibacterial properties, and antibacterial maintenance properties. Therefore, the medical device of the present invention can be suitably used for artificial blood vessels, catheters, and artificial lung systems (artificial lung membranes) that come into contact with a large amount of blood, particularly artificial lung systems (artificial lung membranes) for long-term auxiliary circulation.
  • artificial lung systems artificial lung membranes
  • the material and shape of the base material (base material constituting the medical device) to which the copolymer according to the present invention can be immobilized are not particularly limited.
  • the material may be composed of any material, and the material is not particularly limited. Specific examples include metal materials, polymer materials, and ceramics.
  • the metal material is not particularly limited, and metal materials generally used for medical devices such as catheters, guide wires, and indwelling needles are used.
  • various stainless steels such as SUS304, SUS316, SUS316L, SUS420J2, and SUS630, gold, platinum, silver, copper, nickel, cobalt, titanium, iron, aluminum, tin, or nickel-titanium (Ni-Ti) ) Alloys, nickel-cobalt (Ni—Co) alloys, cobalt-chromium (Co—Cr) alloys, various alloys such as zinc-tungsten (Zn—W) alloys, and the like. These may be used individually by 1 type and may use 2 or more types together. What is necessary is just to select suitably the metal material optimal as base materials, such as a catheter, a guide wire, and an indwelling needle which are use uses as the said metal material.
  • the polymer material is not particularly limited, and polymer materials generally used for medical devices such as catheters, guide wires, and indwelling needles are used.
  • a polyolefin resin such as a polyamide resin, a linear low density polyethylene (LLDPE), a low density polyethylene (LDPE), a high density polyethylene (HDPE), or a polypropylene resin, a modified polyolefin resin, an epoxy resin, Urethane resin, diallyl phthalate resin (allyl resin), polycarbonate resin, fluororesin, amino resin (urea resin, melamine resin, benzoguanamine resin), polyester resin, styrene resin, acrylic resin, polyacetal resin, vinyl acetate resin, phenol resin, chloride A vinyl resin, a silicone resin (silicon resin), a polyether resin, a polyimide resin, etc.
  • polymeric material optimal as base materials, such as a catheter, a guide wire, and an indwelling needle which are use uses as the said polymeric material.
  • the form of the substrate is not limited to a molded body using the above-mentioned material alone, and a blend molded article, an alloyed molded article, a multilayered molded article, and the like can also be used.
  • the coating layer copolymer according to the present invention
  • a material that can be satisfactorily swollen by a solvent is preferred.
  • the shape of the substrate is not particularly limited, and various shapes such as a sheet shape and a tube shape can be used according to the type of medical device to be applied.
  • the coat layer is formed on at least one surface of the substrate and covers the substrate.
  • the “coating” is not limited to a form in which the entire surface of the substrate is completely covered with the coat layer (copolymer according to the present invention), but only a part of the surface of the substrate is coated layer (the present invention).
  • (Copolymer according to the present invention) that is, a form in which a coat layer is formed only on a part of the surface of the substrate (the copolymer according to the present invention is attached) is also included.
  • the coat layer includes the copolymer according to the present invention.
  • the coat layer may contain other additives, drugs (bioactive substances), and the like.
  • the coat layer is preferably composed only of the copolymer according to the present invention.
  • the medical device of the present invention preferably has a structure in which the coating layer according to the present invention is directly formed on a substrate.
  • a substance for example, a solvent, a surfactant, etc.
  • a substance used in producing the copolymer according to the present invention may remain in the coat layer.
  • a form is acceptable. It is included in the form comprised from.
  • the coat layer is coated (fixed) on the surface of the substrate.
  • the method for coating (fixing) the copolymer (medical coating material) according to the present invention on the surface of the substrate is not particularly limited except that the copolymer according to the present invention is used, and a known method is similarly used. Or it can modify and apply suitably.
  • a method of preparing a coating solution by dissolving the copolymer according to the present invention in a solvent and coating the coating solution on a substrate of a medical device can be used.
  • the coat layer is firmly bonded (immobilized) to the surface of the base material, and exhibits good thrombus adhesion suppression / prevention properties, thrombus adhesion suppression / prevention maintenance properties, antibacterial properties, and antibacterial maintenance properties. Can do.
  • the solvent used for dissolving the copolymer according to the present invention is not particularly limited as long as it can dissolve the copolymer according to the present invention.
  • water alcohols such as methanol, ethanol, isopropanol and ethylene glycol, ketones such as acetone and methyl ethyl ketone, esters such as ethyl acetate, halides such as chloroform, olefins such as hexane, tetrahydrofuran (THF ), Ethers such as butyl ether, aromatics such as benzene and toluene, amides such as N, N-dimethylformamide (DMF), and the like, but are not limited thereto.
  • alcohols such as methanol, ethanol, isopropanol and ethylene glycol
  • ketones such as acetone and methyl ethyl ketone
  • esters such as ethyl acetate
  • halides such as chloro
  • the concentration of the copolymer according to the present invention in the coating solution is not particularly limited. From the viewpoint of easy application, desired effects (for example, coatability, thrombus adhesion suppression / prevention, thrombus adhesion suppression / prevention maintenance, antibacterial property, antibacterial maintenance property), the present invention in the coating liquid is used.
  • the concentration of the copolymer is preferably 0.01 to 20% by weight, more preferably 0.05 to 15% by weight, and still more preferably 0.1 to 10% by weight. When the concentration of the copolymer is within the above range, the coatability, thrombus adhesion suppression / prevention property, thrombus adhesion suppression / prevention maintenance property, antibacterial property, and antibacterial maintenance property of the resulting coating layer can be sufficiently exhibited.
  • a uniform coating layer having a desired thickness can be easily obtained by a single coating operation, which is preferable in terms of production efficiency.
  • the copolymer concentration is less than 0.01% by weight, a sufficient amount of copolymer may not be bonded (immobilized) to the substrate surface.
  • the copolymer concentration exceeds 20% by weight, the viscosity of the coating solution becomes too high, and a copolymer with a uniform thickness cannot be bonded (immobilized) to the substrate surface, or the substrate surface is quickly coated. May be difficult. However, even if it is out of the above range, it can be sufficiently utilized as long as it does not affect the operational effects of the present invention.
  • the method for coating the surface of the substrate with the coating liquid is not particularly limited, and is a coating / printing method, dipping method (dipping method, dip coating method), spraying method (spray method), spin coating method, mixed solution. Conventionally known methods such as an impregnation sponge coating method can be applied. Of these, the dipping method (dipping method, dip coating method) is preferably used.
  • the base material when forming a coat layer on a thin and narrow inner surface such as an artificial lung membrane or a catheter, the base material may be immersed in the coating solution, and the inside of the system may be depressurized to be defoamed. By defoaming under reduced pressure, the coating liquid can quickly penetrate into the narrow and narrow inner surface, and the formation of the coating layer can be promoted.
  • an appropriate member that can be attached / detached (attached / removed) on the surface portion of the base material that does not require the formation of a coating layer in advance After the substrate is dipped in the coating liquid and coated with the coating liquid after being protected with a coating material (such as coating), a protective member for the surface portion of the substrate that does not require the formation of a coating layer (
  • the coating layer can be formed on a desired surface portion of the substrate by removing the material) and then drying it by a heating operation or the like.
  • the forming method is not limited to these forming methods, and the coating layer can be formed by appropriately using conventionally known methods.
  • a coating method for example, spraying the coating liquid on a predetermined surface portion of the medical device
  • a coating method using a coating apparatus such as an apparatus, a bar coater, a die coater, a reverse coater, a comma coater, a gravure coater, a spray coater, or a doctor knife
  • a coating apparatus such as an apparatus, a bar coater, a die coater, a reverse coater, a comma coater, a gravure coater, a spray coater, or a doctor knife
  • both the outer surface and the inner surface of the cylindrical device need to have a coat layer due to the structure of the medical device, both the outer surface and the inner surface can be coated at once.
  • the dipping method (dipping method) is preferably used.
  • the drying conditions of the coating solution are not particularly limited as long as the coating layer (coating) containing the copolymer can be formed on the substrate.
  • the drying temperature is preferably 20 to 200 ° C, more preferably 25 to 50 ° C.
  • the drying time is preferably 30 minutes to 24 hours, more preferably 1 to 10 hours. Under such conditions, the coat layer (coating) of the copolymer according to the present invention can be firmly fixed on the surface of the substrate.
  • the pressure condition at the time of drying is not limited at all, and it can be performed under normal pressure (atmospheric pressure), or under pressure or reduced pressure.
  • drying means for example, an oven or a vacuum dryer can be used.
  • the drying means is not particularly required.
  • the cross-linking reaction may be further performed before or after forming the coat layer (coating) of the copolymer according to the present invention on the substrate surface by the above method.
  • a stronger coating layer that does not easily peel from the substrate can be formed.
  • the medical device according to the present invention has a coat layer (film) formed of the copolymer according to the present invention on the surface. For this reason, the medical device by this invention can exhibit the outstanding thrombus adhesion suppression / prevention property, thrombus adhesion suppression / prevention maintenance property, antibacterial property, and antibacterial maintenance property.
  • the crosslinking reaction is performed under mild conditions in which the carbonyl group in the hydrophilic vinyl monomer is present in the presence of a crosslinking agent. Yes.
  • the medical coating material containing a copolymer having a structural unit derived from a hydrophilic vinyl monomer having a crosslinkable side chain does not require heating or the like, under mild conditions that do not impair the physical properties of the substrate itself, It can be simply crosslinked or bonded (immobilized) to the surface of the substrate.
  • the crosslinking agent can be appropriately selected depending on the type of hydrophilic vinyl monomer to be used.
  • the hydrophilic vinyl monomer having a crosslinkable side chain of the formula (1) is not particularly limited as long as it can react with a carbonyl group in the hydrophilic vinyl monomer to form a covalent bond.
  • the hydrazide compound has at least two hydrazine residues. That is, the coat layer is formed of a reaction product of the copolymer according to the present invention (or the hydrophilic vinyl monomer of the formula (1)) and a hydrazide compound having at least two hydrazine residues per molecule. preferable.
  • the hydrazine residue forms a covalent bond with the carbonyl group under mild conditions, particularly at room temperature, thereby strengthening the copolymer according to the present invention without impairing the physical properties originally required for the substrate itself. It becomes possible to fix to the substrate surface.
  • a proton-donating solvent can also be used, and it is not necessary to perform strict moisture management in the work area during the reaction.
  • hydrazide compound examples include adipic acid dihydrazide, carbohydrazide, 1,3-bis (hydrazinocarboethyl) -5-isopropylhydantoin, and the like.
  • a polymer or copolymer obtained by treating a poly (meth) acrylic ester with a hydrazine residue after polymerization, or a polymer of a monomer previously treated with a hydrazine residue at the time of the monomer, or Copolymers are also included.
  • adipic acid dihydrazide is preferable from the viewpoint of solubility in water.
  • the crosslinking reaction between the hydrazide compound and the copolymer according to the present invention proceeds at room temperature as described above, and usually no addition of a catalyst is necessary. It can be accelerated by adding a water-soluble metal salt such as zinc sulfate, manganese sulfate, cobalt sulfate or the like, or by heating and drying.
  • the heating temperature for the heat drying is preferably 40 to 150 ° C., more preferably 40 to 60 ° C., from the viewpoint of not deteriorating the physical properties of the substrate.
  • crosslinking agents are applied at a ratio of 1 to 200 parts by weight, preferably 10 to 100 parts by weight, based on 100 parts by weight of the copolymer according to the present invention (or the hydrophilic vinyl monomer of the formula (1)). It is desirable.
  • the weight average molecular weight of the polymer was measured using GPC (manufactured by Showa Denko KK, apparatus: SHODEX (registered trademark) GPC system; standard material: polystyrene).
  • the composition of each copolymer was measured by neutralization titration.
  • Example 1 Vinylimidazole (VIm) 3.57 g (38 mmol) and diacetone acrylamide (DAAM) 6.43 g (38 mmol) were dissolved in 40 g of dioxane, placed in a four-necked flask, and N 2 bubbling was performed at 80 ° C. for 1 hour. It was. Separately, a solution obtained by dissolving 0.1 g of azobisisobutyronitrile (AIBN) in 1 mL of dioxane was added to the obtained mixed solution, and polymerization was performed at 80 ° C. for 5 hours. The obtained polymerization solution was dropped into hexane, and the precipitated polymer was collected.
  • AIBN azobisisobutyronitrile
  • Example 2 2.17 g (23 mmol) of vinylimidazole (VIm) and 7.82 g (46 mmol) of diacetone acrylamide (DAAM) were dissolved in 40 g of dioxane, placed in a four-necked flask, and N 2 bubbling was performed at 80 ° C. for 1 hour. . Separately, a solution obtained by dissolving 0.1 g of azobisisobutyronitrile (AIBN) in 1 mL of dioxane was added to the obtained mixed solution, and polymerization was performed at 80 ° C. for 5 hours. The obtained polymerization solution was dropped into hexane, and the precipitated polymer was collected.
  • AIBN azobisisobutyronitrile
  • Example 3 Vinylimidazole (VIm) 1.0 g (10 mmol) and diacetone acrylamide (DAAM) 9.0 g (50 mmol) were dissolved in 40 g of dioxane, placed in a four-necked flask, and N 2 bubbling was performed at 80 ° C. for 1 hour. . Separately, a solution obtained by dissolving 0.1 g of azobisisobutyronitrile (AIBN) in 1 mL of dioxane was added to the obtained mixed solution, and polymerization was performed at 80 ° C. for 5 hours. The obtained polymerization solution was dropped into hexane, and the precipitated polymer was collected.
  • AIBN azobisisobutyronitrile
  • Example 4 12.1 g (130 mmol) of vinylimidazole (VIm) and 7.9 g (60 mmol) of butyl methacrylate (BMA) were dissolved in 80 g of dioxane, placed in a four-necked flask, and N 2 bubbling was performed at 80 ° C. for 1 hour. Separately, a solution obtained by dissolving 0.2 g of azobisisobutyronitrile (AIBN) in 1 mL of dioxane was added to the obtained mixed solution, and polymerization was performed at 80 ° C. for 5 hours. The obtained polymerization solution was dropped into hexane, and the precipitated polymer was collected.
  • AIBN azobisisobutyronitrile
  • Example 5 8.5 g (90 mmol) of vinylimidazole (VIm) and 13 g (90 mmol) of butyl methacrylate (BMA) were dissolved in 80 g of dioxane, put into a four-necked flask, and N 2 bubbling was performed at 80 ° C. for 1 hour. Separately, a solution obtained by dissolving 0.2 g of azobisisobutyronitrile (AIBN) in 1 mL of dioxane was added to the obtained mixed solution and polymerized at 80 ° C. for 5 hours. The obtained polymerization solution was dropped into hexane, and the precipitated polymer was collected.
  • AIBN azobisisobutyronitrile
  • Example 6 0.9 g (10 mmol) of vinylimidazole (VIm) and 9.0 g (53 mmol) of diacetone acrylamide (DAAM) were dissolved in 40 g of dioxane, placed in a four-necked flask, and N 2 bubbling was performed at 80 ° C. for 1 hour. It was. Separately, a solution obtained by dissolving 0.1 g of azobisisobutyronitrile (AIBN) in 1 mL of dioxane was added to the obtained mixed solution, and polymerization was performed at 80 ° C. for 5 hours. The obtained polymerization solution was dropped into hexane, and the precipitated polymer was collected.
  • AIBN azobisisobutyronitrile
  • Platelet adhesion test The number of platelet adhesion (thrombosis) was measured according to the following method for the substrate coated with the copolymers (1) to (6) obtained in Examples 1 to 6 and the uncoated substrate (Comparative Example 1). Adhesion suppression / prevention) was evaluated.
  • each polymer was dissolved in acetone at a concentration of 0.5% by weight.
  • a polypropylene film (FOP50, manufactured by Nimura Chemical) (size: 20 mm ⁇ 50 mm) as a base material is immersed for 1 minute at room temperature (25 ° C.) and then dried at room temperature (25 ° C.) for 120 minutes.
  • FOP50 manufactured by Nimura Chemical
  • a coating layer of each polymer was formed on the substrate.
  • covered with a polymer was made into the comparative example 1.
  • the base material on which the coat layer of each polymer is formed or an uncoated polypropylene film and human fresh platelet-rich plasma anticoagulated with sodium citrate are contacted for 30 minutes, rinsed with physiological saline, and glutaraldehyde Then, the number of adhered platelets was measured under an electron microscope. The total number of platelet adhesion in 1000 times 5 visual fields was calculated. The results are shown in Table 1. Further, after the platelet adhesion test, the surfaces of the polypropylene film on which the coating layer of the copolymer (3) obtained in Example 3 was formed and the uncoated polypropylene film (Comparative Example 1) were scanned with a scanning electron microscope (SEM). The results are shown in FIGS. 1 and 2, respectively.
  • SEM scanning electron microscope
  • the base material (medical device) having the coating layer of the copolymer according to the present invention significantly adheres to platelets (adhesion) as compared to the uncoated base material (Comparative Example 1). ) Is suppressed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention porte sur un matériau de revêtement médical qui a d'excellentes propriétés hydrophiles et sur un dispositif médical qui est revêtu dudit matériau. Ce matériau de revêtement médical comprend un copolymère qui comprend un segment A ayant des motifs constitutifs issus de vinylimidazole et un segment B ayant des motifs constitutifs issus de monomère vinylique.
PCT/JP2014/052322 2013-02-08 2014-01-31 Matériau de revêtement médical et dispositif médical WO2014123077A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013-023693 2013-02-08
JP2013023693A JP2016063846A (ja) 2013-02-08 2013-02-08 医療用コーティング材料および医療用具

Publications (1)

Publication Number Publication Date
WO2014123077A1 true WO2014123077A1 (fr) 2014-08-14

Family

ID=51299672

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2014/052322 WO2014123077A1 (fr) 2013-02-08 2014-01-31 Matériau de revêtement médical et dispositif médical

Country Status (2)

Country Link
JP (1) JP2016063846A (fr)
WO (1) WO2014123077A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017154527A1 (fr) * 2016-03-08 2017-09-14 テルモ株式会社 Instrument médical

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06508645A (ja) * 1991-06-27 1994-09-29 バイオインターラクションズ　リミテッド ポリマー被覆物
JP2002105136A (ja) * 2000-09-29 2002-04-10 Terumo Corp 抗血栓性表面処理剤および医療用具
JP2003506111A (ja) * 1999-01-22 2003-02-18 ザ ダウ ケミカル カンパニー 血液適合性コーティングを有する表面改質ジビニルベンゼン樹脂
JP2013169283A (ja) * 2012-02-20 2013-09-02 Terumo Corp 医療用具の製造方法および医療用具

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06508645A (ja) * 1991-06-27 1994-09-29 バイオインターラクションズ　リミテッド ポリマー被覆物
JP2003506111A (ja) * 1999-01-22 2003-02-18 ザ ダウ ケミカル カンパニー 血液適合性コーティングを有する表面改質ジビニルベンゼン樹脂
JP2002105136A (ja) * 2000-09-29 2002-04-10 Terumo Corp 抗血栓性表面処理剤および医療用具
JP2013169283A (ja) * 2012-02-20 2013-09-02 Terumo Corp 医療用具の製造方法および医療用具

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017154527A1 (fr) * 2016-03-08 2017-09-14 テルモ株式会社 Instrument médical
CN108601934A (zh) * 2016-03-08 2018-09-28 泰尔茂株式会社 医疗用具
JPWO2017154527A1 (ja) * 2016-03-08 2019-01-17 テルモ株式会社 医療用具
US10751521B2 (en) 2016-03-08 2020-08-25 Terumo Kabushiki Kaisha Medical instrument
CN108601934B (zh) * 2016-03-08 2021-05-07 泰尔茂株式会社 医疗用具

Also Published As

Publication number Publication date
JP2016063846A (ja) 2016-04-28

Similar Documents

Publication Publication Date Title
JP6495241B2 (ja) 医療用具の製造方法および医療用具
US9782521B2 (en) Medical device and method for producing medical device
JP6619360B2 (ja) 医療用具およびその製造方法
US10022478B2 (en) Medical device
JP5969484B2 (ja) 抗血栓性材料および医療用具
US9956324B2 (en) Medical material, and medical device using the medical material
WO2019142710A1 (fr) Matériau de revêtement médical et instrument médical utilisant ledit matériau de revêtement médical
WO2011158642A1 (fr) Procédé pour produire un dispositif médical
WO2014123077A1 (fr) Matériau de revêtement médical et dispositif médical
JP6110186B2 (ja) 潤滑コート剤および医療デバイス
JPWO2020004385A1 (ja) 親水性共重合体および医療用具
JP6456196B2 (ja) 抗血栓性接着用組成物、ならびに該抗血栓性接着用組成物を利用した医療用具およびその製造方法
JP2014147639A (ja) 医療用具
JP2016150163A (ja) 医療用具の製造方法
JPWO2019059106A1 (ja) 医療用具の製造方法
JPWO2020175329A1 (ja) 医療用具の製造方法および医療用具
JP2020039826A (ja) 医療用具の製造方法および医療用具

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14749313

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14749313

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP